Aligos Therapeutics (ALGS) Other Operating Expenses (2019 - 2026)

Aligos Therapeutics has reported Other Operating Expenses for 8 years, with the latest figure at $811000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 7.84% year-over-year to $811000.0; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 2.8% YoY), and the FY2025 full-year result was $3.9 million, down 10.99% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $811000.0, up from $750000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $1.6 million in Q1 2024, with the low at -$5000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $837176.5 across 5 years, with a median of $880000.0 in 2025.
• Annual changes were most pronounced in 2022 — Other Operating Expenses sank 104.5% — and 2023, when it surged 20140.0%.
• Aligos Therapeutics' Other Operating Expenses stood at $845000.0 in 2022, then tumbled by 71.12% to $244000.0 in 2023, then jumped by 134.84% to $573000.0 in 2024, then surged by 30.89% to $750000.0 in 2025, then increased by 8.13% to $811000.0 in 2026.
• The last three Other Operating Expenses figures came in at $811000.0 (Q1 2026), $750000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.